Advances in the Treatment of Immune Thrombocytopenia: Strategies for Optimizing Clinical and Patient Outcomes

Program Description

Immune thrombocytopenia (ITP) is a complex disorder of immune dysregulation in which B cells and plasma cells produce autoantibodies that bind platelets and platelet-producing megakaryocytes leading to their degradation or impairment. In patients with ITP, the number of platelets is significantly reduced, causing an increased likelihood of bleeding and decreased quality of life. ITP can be primary (occurs in isolation) or secondary (in association with other disorders). Secondary causes include autoimmune diseases such as anti-phospholipid antibody syndrome, viral infections, and certain drugs. Pharmacists can be integral to the treatment and management of therapies for patients with ITP and should be familiar with current guideline recommendations and emerging therapies to optimize therapy in this patient population. This activity will review current strategies for the selection of appropriate ITP therapy to improve clinical decision-making among the health care team. The podcast discussion will focus on individualized treatment plans, the importance of laboratory monitoring and adherence, and the pharmacist’s role in facilitating continuity of care to improve health-related quality of life for patients with ITP.

Target audience: Health-system pharmacists, retail pharmacists, and specialty pharmacists

Type of activity: Knowledge
Release date: December 19, 2022
Expiration date: December 19, 2023

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Outline current guideline recommendations and strategies pharmacists can implement for the management of immune thrombocytopenia (ITP)
• Recall the efficacy and safety of emerging agents for the treatment of ITP

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.1 CEU) under the ACPE universal activity number 0290-0000-22-608-H01-P. The activity is available for CE credit through December 19, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Anthony J. Perissinotti, PharmD, BCOP has the following relevant financial relationships with commercial interests to disclose:
Consultant: AbbVie, BeiGene, Janssen

Lisa Charneski, PharmD, BCPS, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Karleen Melody, PharmD; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms